Profile of:

Uta Kiltz

Uta Kiltz is a senior rheumatologist at Rheumazentrum Ruhrgebiet and a clinical lecturer, Ruhr University Bochum, Germany. She is a clinical rheumatologist with research interests and expertise in the diagnosis and management of inflammatory rheumatic diseases including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis (SpA), and gouty arthritis. She is also a lead coordinator for publishing national recommendation for axial spondyloarthritis and gouty arthritis. She has a special interest in SpA, particularly on patient-reported outcomes (PROs) and quality instruments. Over the past years, she has actively contributed to develop and translate PROs for patients with SpA (ASAS Health Index (ASAS HI), Psoriatic Arthritis Impact of Disease (PSAID), and translation into German (Psoriatic Arthritis Quality of Life (PSAQoL), Osteoarthritis Quality of Life (OAQoL), Fibromyalgia Raid Screening Tool (FiRST)). The ASAS Health Index (ASAS HI) is a unique questionnaire since it is the first questionnaire ever which is based on the International Classification of Functioning, Disability, and Health (ICF). Recently, she coordinate the development of the ASAS quality standards for assessing the quality of care in patients with axSpA. Uta Kiltz attended medical school at Ruhr University Bochum, Germany, and trained at the university hospital in Bochum before she moved to Rheumazentrum Ruhrgebiet to complete training in rheumatology. She is a member of international committees and organizations like the Assessment of Spondyloarthritis International Society (ASAS), European League Against Rheumatism (EULAR) as well as the German Society for Rheumatology (DGRh).

Full name: Uta Kiltz

Current country: Germany

Membership level: Full

Type of membership: Member

Number of publications: 18

The ASAS-OMERACT core domain set for axial spondyloarthritis (2021)

Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study (2021)

Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies (2021)

Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study (2021)

[Development of quality standards for patients with axial spondyloarthritis for use in Germany] (2021)

Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial Spondyloarthritis (2021)

Treat-to-target in axial spondyloarthritis – what about physical function and activity? (2021)

Domains to Be Considered for the Core Outcome Set of Axial Spondyloarthritis: Results From a 3-round Delphi Survey (2021)

Which Magnetic Resonance Imaging Lesions in the Sacroiliac Joints Are Most Relevant for Diagnosing Axial Spondyloarthritis? A Prospective Study Comparing Rheumatologists’ Evaluations With Radiologists’ Findings (2021)

Ixekizumab Improves Functioning and Health in the Treatment of Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results, COAST-X Trial (2021)

The European Portuguese version of the ASAS Health Index for Patients with Spondyloarthritis: Measurement properties (2020)

[Is it possible to delegate medical services to qualified nurses specialized in rheumatology when evaluating patients with suspicion of ankylosing spondylitis?-Results of the PredAS study] (2020)

Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis (2020)

(Health-Related) Quality of Life as an Outcome in Studies of Axial Spondyloarthritis (2020)

Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis (2020)

Development of one general and six country-specific algorithms to assess societal health utilities based on ASAS HI (2019)

[Identification of patients with axial spondylarthritis in primary care (AWARE study)] (2019)

[Epionics SPINE-use of an objective method to examine spinal mobility in patients with axial spondyloarthritis] (2002)